Literature DB >> 27220765

Impact of the 2013 ASCO/CAP HER2 revised guidelines on HER2 results in breast core biopsies with invasive breast carcinoma: a retrospective study.

Wynton B Overcast1, Jianying Zhang2, Debra L Zynger3, Gary H Tozbikian4.   

Abstract

Entities:  

Keywords:  ASCO/CAP guidelines; Breast cancer; Equivocal category; HER2 fluorescence in situ hybridization (FISH); HER2 immunohistochemistry (IHC)

Mesh：

Substances：

Year:  2016        PMID： 27220765     DOI： 10.1007/s00428-016-1951-8

Source DB:  PubMed          Journal:  Virchows Arch        ISSN： 0945-6317            Impact factor:   4.064


× No keyword cloud information.
  21 in total

1.  Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.

Authors:  Tse Hui Lim; Alvin Soon Tiong Lim; Aye Aye Thike; Sim Leng Tien; Puay Hoon Tan
Journal:  Arch Pathol Lab Med       Date:  2016-02       Impact factor: 5.534

2.  American Society of Clinical Oncology/College of American Pathologists Human Epidermal Growth Factor Receptor 2 Testing Clinical Practice Guideline Upcoming Modifications: Proof That Clinical Practice Guidelines Are Living Documents.

Authors:  M Elizabeth H Hammond; David G Hicks
Journal:  Arch Pathol Lab Med       Date:  2015-04-17       Impact factor: 5.534

Review 3.  Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer.

Authors:  D Craig Allred
Journal:  Mod Pathol       Date:  2010-05       Impact factor: 7.842

4.  The New Equivocal: Changes to HER2 FISH Results When Applying the 2013 ASCO/CAP Guidelines.

Authors:  Thomas H Long; Helen Lawce; Connie Durum; Stephen R Moore; Susan B Olson; Ken Gatter; Megan L Troxell
Journal:  Am J Clin Pathol       Date:  2015-08       Impact factor: 2.493

5.  High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study.

Authors:  David J Dabbs; Molly E Klein; Syed K Mohsin; Raymond R Tubbs; Yongli Shuai; Rohit Bhargava
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

6.  HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.

Authors:  Edith A Perez; Monica M Reinholz; David W Hillman; Kathleen S Tenner; Matthew J Schroeder; Nancy E Davidson; Silvana Martino; George W Sledge; Lyndsay N Harris; Julie R Gralow; Amylou C Dueck; Rhett P Ketterling; James N Ingle; Wilma L Lingle; Peter A Kaufman; Daniel W Visscher; Robert B Jenkins
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

7.  Correlation between HER2 determined by fluorescence in situ hybridization and reverse transcription-polymerase chain reaction of the oncotype DX test.

Authors:  Leah Dvorak; Michelle Dolan; James Fink; Linda Varghese; Jonathan Henriksen; H Evin Gulbahce
Journal:  Appl Immunohistochem Mol Morphol       Date:  2013-05

8.  ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment.

Authors:  MiHee M Park; Joshua J Ebel; Weiquiang Zhao; Debra L Zynger
Journal:  Breast J       Date:  2013-11-22       Impact factor: 2.431

9.  Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.

Authors:  Mitch Dowsett; Marion Procter; Worta McCaskill-Stevens; Evandro de Azambuja; Urania Dafni; Josef Rueschoff; Bruce Jordan; Stella Dolci; Mark Abramovitz; Oliver Stoss; Giuseppe Viale; Richard D Gelber; Martine Piccart-Gebhart; Brian Leyland-Jones
Journal:  J Clin Oncol       Date:  2009-04-13       Impact factor: 44.544

10.  Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network.

Authors:  A Borley; T Mercer; M Morgan; P Dutton; P Barrett-Lee; M Brunelli; B Jasani
Journal:  Br J Cancer       Date:  2014-04-01       Impact factor: 7.640
View more
  2 in total

1.  Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.

Authors:  Michael F Press; Jose A Seoane; Christina Curtis; Emmanuel Quinaux; Roberta Guzman; Guido Sauter; Wolfgang Eiermann; John R Mackey; Nicholas Robert; Tadeusz Pienkowski; John Crown; Miguel Martin; Vicente Valero; Valerie Bee; Yanling Ma; Ivonne Villalobos; Dennis J Slamon
Journal:  JAMA Oncol       Date:  2019-03-01       Impact factor: 31.777

2.  Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis.

Authors:  Matthias Christgen; Jana L van Luttikhuizen; Mieke Raap; Peter Braubach; Lars Schmidt; Danny Jonigk; Friedrich Feuerhake; Ulrich Lehmann; Brigitte Schlegelberger; Hans H Kreipe; Doris Steinemann
Journal:  Oncotarget       Date:  2016-12-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.